1. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
- Author
-
Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, Enrico Silini, Jan von der Thüsen, Nesa Marti, Karerina Vervita, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Paul Baas, Isabelle Opitz, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Barbara Ruepp, Urania Dafni, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Eric Verbeken, Birgit Weyenand, Liesbet Peeters, Marcello Tiseo, Enrico Maria Silini, Luigi Ventura, Letizia Gnetti, Paolo Carbognani, Fatemeh B. Zaeimi, Sven Seiwerth, Marko Jakopovic, Felipe Cardenal, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Paraskevi Boura, Steven Gray, Mutaz Mohammed Nur, Anne-Marie Baird, Martin Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts, University of Zurich, Pulmonary Medicine, and Pathology
- Subjects
Mesothelioma ,Phosphatidylinositol 3-Kinases / metabolism ,Ribosomal Protein S6 ,Lung Neoplasms ,Pronòstic mèdic ,10255 Clinic for Thoracic Surgery ,Pleural Neoplasms ,Lung Neoplasms / pathology ,Mesothelioma, Malignant ,Pleural Neoplasms / pathology ,610 Medicine & health ,Sarcoma ,Prognosis ,Pathology and Forensic Medicine ,Phosphatidylinositol 3-Kinases ,Mesotelioma ,10049 Institute of Pathology and Molecular Pathology ,Càncer de pulmó ,Pleura ,Humans ,Lung cancer ,ETOP Mesoscape consortium ,Mesothelioma / pathology - Abstract
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p
- Published
- 2022
- Full Text
- View/download PDF